Tasly Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has an Asset Resilience Ratio of 9.09% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600535 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Tasly Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See 600535 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tasly Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Tasly Pharmaceutical Group Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.39 Billion | 9.09% |
| Total Liquid Assets | CN¥1.39 Billion | 9.09% |
Asset Resilience Insights
- Limited Liquidity: Tasly Pharmaceutical Group Co Ltd maintains only 9.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tasly Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tasly Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Tasly Pharmaceutical Group Co Ltd (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Tasly Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.09% | CN¥1.39 Billion ≈ $204.00 Million |
CN¥15.34 Billion ≈ $2.24 Billion |
+5.58pp |
| 2024-12-31 | 3.50% | CN¥524.72 Million ≈ $76.78 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+1.70pp |
| 2023-12-31 | 1.80% | CN¥300.71 Million ≈ $44.00 Million |
CN¥16.71 Billion ≈ $2.45 Billion |
-5.05pp |
| 2022-12-31 | 6.85% | CN¥1.12 Billion ≈ $164.62 Million |
CN¥16.43 Billion ≈ $2.40 Billion |
-2.15pp |
| 2021-12-31 | 8.99% | CN¥1.49 Billion ≈ $217.66 Million |
CN¥16.54 Billion ≈ $2.42 Billion |
+8.13pp |
| 2020-12-31 | 0.87% | CN¥142.92 Million ≈ $20.91 Million |
CN¥16.49 Billion ≈ $2.41 Billion |
+0.62pp |
| 2019-12-31 | 0.25% | CN¥59.39 Million ≈ $8.69 Million |
CN¥24.01 Billion ≈ $3.51 Billion |
-0.38pp |
| 2018-12-31 | 0.63% | CN¥158.30 Million ≈ $23.16 Million |
CN¥25.17 Billion ≈ $3.68 Billion |
-1.94pp |
| 2017-12-31 | 2.57% | CN¥552.66 Million ≈ $80.87 Million |
CN¥21.53 Billion ≈ $3.15 Billion |
+1.00pp |
| 2016-12-31 | 1.56% | CN¥267.90 Million ≈ $39.20 Million |
CN¥17.13 Billion ≈ $2.51 Billion |
-0.19pp |
| 2015-12-31 | 1.76% | CN¥270.50 Million ≈ $39.58 Million |
CN¥15.41 Billion ≈ $2.26 Billion |
+1.39pp |
| 2014-12-31 | 0.36% | CN¥46.85 Million ≈ $6.86 Million |
CN¥12.92 Billion ≈ $1.89 Billion |
-0.47pp |
| 2013-12-31 | 0.83% | CN¥84.96 Million ≈ $12.43 Million |
CN¥10.21 Billion ≈ $1.49 Billion |
+0.58pp |
| 2012-12-31 | 0.25% | CN¥19.00 Million ≈ $2.78 Million |
CN¥7.49 Billion ≈ $1.10 Billion |
-0.36pp |
| 2006-12-31 | 0.61% | CN¥20.04 Million ≈ $2.93 Million |
CN¥3.26 Billion ≈ $477.01 Million |
-2.66pp |
| 2005-12-31 | 3.27% | CN¥90.08 Million ≈ $13.18 Million |
CN¥2.75 Billion ≈ $403.06 Million |
+2.82pp |
| 2004-12-31 | 0.46% | CN¥10.02 Million ≈ $1.47 Million |
CN¥2.20 Billion ≈ $322.08 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more